Brief: Monte Rosa Therapeutics Announces Fourth Quarter 2022 Financial Results
16/03/2023 11:43
March 16 (Reuters) - Monte Rosa Therapeutics Inc
GLUE.O :
* MONTE ROSA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL
YEAR
2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* NET LOSS FOR Q4 OF 2022 WAS $30.8 MILLION COMPARED TO
$23.4
MILLION FOR Q4 OF 2021
* DISCLOSURE OF INITIAL DATA FROM PHASE 1 ARM OF STUDY
EXPECTED IN
SECOND HALF OF 2023
* Q4 NET LOSS PER SHARE - BASIC AND DILUTED $0.63
Source text for Eikon: ID:nGNX2Zb84T
Further company coverage: GLUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million